New eye drug shows promise in early safety trial for blinding disease
NCT ID NCT05953012
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-stage study tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to check the drug's safety and find the best dose for future studies. Participants received the drug by injection into the eye and were closely monitored for side effects and changes in vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASAN Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Seoul National University Bundang Hospital
Seoul, Bundang-gu, 13620, South Korea
-
Yeungnam University
Daegu, Nam-gu, 42415, South Korea
-
Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
Conditions
Explore the condition pages connected to this study.